Expert Consensus Group on Drug Clinical Trial Design and Implementation, Fuwai Hospital, Chinese Academy of Medical Sciences, National Center for Cardiovascular Diseases; Cardiovascular Clinical Research Group, Chinese Society of Cardiovascular Diseases, Email: jing.li@fwoxford.org
Export PDF Favorites Scan Get Citation

Clinical trials are the most reliable means for scientifically rigorous evaluation of the efficacy and safety of drugs, and are the most crucial part receiving the most investment in development and innovation in the pharmaceutical industry. In recent years, the nation has formulated a set of policies and guiding principles to encourage pharmaceutical innovation, promote the independent innovation of China’s pharmaceutical industry and enhance clinical trial capacity. To further improve Chinese researchers’ ability to perform clinical trials, the National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and the National Center for Cardiovascular Diseases invited a multi-disciplinary team of experts from various areas including clinical trial methodology and supervision to work on this consensus. In view of the common concern and puzzles regarding the issues in clinical trials, such as recruitment and retention of participants, outcome selection, quality control, information technology application, and ethics in data security, the expert consensus is based on domestic and international guidelines, the latest advancement of clinical research, and the advice and opinions from national experts. It aims to provide reference information and guidance for clinical trial researchers, and serves as a reference for relevant authorities to formulate clinical trial management policies.

Citation: Expert Consensus Group on Drug Clinical Trial Design and Implementation, Fuwai Hospital, Chinese Academy of Medical Sciences, National Center for Cardiovascular Diseases; Cardiovascular Clinical Research Group, Chinese Society of Cardiovascular Diseases. Expert consensus on problem-solving strategies for drug clinical trial design and implementation. Chinese Journal of Evidence-Based Medicine, 2022, 22(3): 249-260. doi: 10.7507/1672-2531.202109156 Copy

  • Next Article

    Newborn hereditary deafness genetic screening in Nantong city: a prospective cohort study